Call for Research Grant Assignment | 1232217 | DA-TAC

Description

Offer Description: The University of Coimbra opens a call for the assignment of a research grant, with two position(s), under the project CENTRO2030-FEDER-02361900 , title DA-TAC (Control of Alzheimer’s disease phenotypes with tacedinaline encapsulated in liposomes) . The call is governed by this Notice of Opening, the University of Coimbra Research Grant Regulations (RBI-UC), subsidiarily by the Research Grant Regulations of the Foundation for Science and Technology (RBI-FCT), by the Research Fellow Statute (EBI), by the Norms for Grant Assignment and Management within R&D Projects, by the Code of Administrative Procedure (CPA), all in their current wording, and by other applicable national and community legislation. Procedure Reference: IT137 -26- 434 I - Legal admission requirements I.I - Grant Recipients: Master’s degree holder in the fields of Neurosciences, Biomedicine, Biology, Biochemistry, Pharmacy or related areas, and be enrolled in a PhD programme or in a non-degreeawarding course in the scientific field of Biomedicine, Biology, Biochemistry or Neuroscience . I.II - The non-degree-granting course must be related to the type of activity covered by the grant. Non-degree-granting courses are defined as those referred to in subparagraph e) of paragraph 3 of Article 4 of Decree-Law No. 74/2006, in its current wording, provided that, under subparagraph e) of Article 3 of RBI-FCT, they are developed in association or cooperation between the higher education institution and one or more R&D units. I.III - Ineligible candidates: Candidates enrolled in non-degree-granting courses who have already benefited from a grant contract and who, with this grant assignment, including possible renewals, exceed a total accumulated period of two consecutive or non-consecutive years in this type of grant. I.IV - Eligible for grant assignment if meeting the requirements: a) Portuguese nationals or nationals of other EU Member States b) Nationals of third countries c) Stateless persons d) Beneficiaries of political refugee status II - Grant location: CNC-UC III- Scientific supervision/coordination of the grant: Ana Cristina Carvalho Rego IV - Work Plan / Goals to be achieved: The project aims to explore a therapeutic application in the context of Alzheimer’s disease (AD). Specifically, the work plan will focus on analyzing the cerebral effects of tacedinaline (Tac), a class I histone deacetylase inhibitor, through its encapsulation in nanoparticles (liposomes) and extracellular vesicles (exosomes), using in vitro, in vivo, and ex vivo models of AD. The candidate will perform the following tasks: 1.Encapsulation of the drug in liposomes and exosomes and their respective characterization; 2.Treatment of neuronal and astrocyte cultures and analysis of markers of cytotoxicity and cellular senescence (in vitro); 3.Administration of the encapsulated drug in an AD animal model and analysis of behavioral alterations (e.g., anxiety, memory) (in vivo); 4.Analysis of pathological changes in brain samples obtained from the AD animal model (ex vivo). V - Initial grant duration: 6 months V.I - Renewal Possibility: Possibily renewable VI - Funding and financial conditions of the grant VI.I - Monthly grant amount (paid by bank transfer at the end of each month): 1 359,64€ VI.II - Other financial components of the grant: N.A. VI.III - In addition to the above amounts, voluntary social security (SSV) is included when the grant has a duration of six months or more, corresponding to the first level, if the candidate opts for it, as well as mandatory personal accident insurance. VI.IV - Funding: The grant(s) assigned under this call will be funded by European Regional Development Fund (FEDER), through the Centro Regional Program 2021-2027 (Centro 2030), by Portugal 2030 and by the European Union | Notice Code: Centro2030-2024-59 | Operation code: CENTRO2030-FEDER-02361900 VI.V - Information and publicity about the funding: In all R&D activities directly or indir

Sectors

Source

Source: euraxess.ec.europa.eu